NCT04935021 is a Phase 4 clinical trial of ATTR-CM in Transthyroxine Amyloidosis Cardiomyopathy, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04935021?

NCT04935021 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04935021?

Interventions in NCT04935021: ATTR-CM.

What condition does NCT04935021 study?

NCT04935021 studies Transthyroxine Amyloidosis Cardiomyopathy.

Is NCT04935021 still recruiting?

NCT04935021 is currently recruiting now. Last updated 31 January 2023.

Last reviewed 2023-01-31 · How we verify

NCT04935021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of ATTR-CM

Recruiting now Phase 4 Last updated 31 January 2023

What this trial tests

Phase 4 trial testing ATTR-CM in Transthyroxine Amyloidosis Cardiomyopathy in 100 participants. Currently enrolling.

Timeline

1 June 2021

Primary endpoint
1 June 2031

1 June 2031

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 June 2021
Primary completion	1 June 2031
Estimated completion	1 June 2031
Sites	1 location across China

Drugs / interventions tested

ATTR-CM — full drug profile →

Conditions studied

Transthyroxine Amyloidosis Cardiomyopathy — all drugs for Transthyroxine Amyloidosis Cardiomyopathy →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 80, any sex, with Transthyroxine Amyloidosis Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Application of next generation sequencing in cardiology: current and future precision medicine implications.
Papadopoulou E, Bouzarelou D, Tsaousis G, Papathanasiou A, et al · · 2023 · cited 6× · PMID 37424920 · DOI 10.3389/fcvm.2023.1202381

Verify or expand the search:

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04935021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 31 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04935021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing